Literature DB >> 24871863

Long-term trends in gender, T-stage, subsite and treatment for laryngeal cancer at a single center.

Jesper Brandstorp-Boesen1, Ragnhild Sørum Falk, Morten Boysen, Kjell Brøndbo.   

Abstract

To investigate the changes in the epidemiology of laryngeal squamous cell carcinoma (LSCC) regarding gender, T-stage and subsite distribution, and to identify the potential effect of introducing new therapeutic alternatives for early and advanced stage LSCC. A prospective cohort study of LSCC patients diagnosed and treated at a single tertiary referral center in Norway. Retrospective analysis of prospectively recorded data from 1,616 patients treated for LSCC in all subsites of the larynx during 1983-2010. Females represented an increasing proportion of cases throughout the study (p < 0.01) and presented more often than men with supraglottic cancer (p < 0.01). Marked changes in the distribution of T-stages over time were observed in both early and advanced stage LSCC. T1a glottic tumors constituted 56 % of all early-stage LSCC and were predominantly treated by transoral endoscopic laser surgery. The introduction of chemoradiotherapy for advanced stage LSCC offers a distinct advantage for laryngeal preservation. The increasing proportion of females with LSCC may be explained by changes in smoking habits. The proportion of T1a glottic LSCC gradually increased over time, while T4 supraglottic LSCC became less frequent. Videostroboscopy should be considered mandatory in the diagnosis and follow-up of LSCC. Transoral laser microsurgery is the standard first-line treatment for T1a glottic tumors. Chemoradiotherapy has reduced the number of total laryngectomies and is now regarded as the primary treatment for advanced stage tumors.

Entities:  

Mesh:

Year:  2014        PMID: 24871863     DOI: 10.1007/s00405-014-3100-9

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  42 in total

1.  Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer.

Authors:  J P Pignon; J Bourhis; C Domenge; L Designé
Journal:  Lancet       Date:  2000-03-18       Impact factor: 79.321

2.  Beyond the 'new' TNM classification.

Authors:  B J Bailey
Journal:  Arch Otolaryngol Head Neck Surg       Date:  1991-04

3.  [Laryngeal carcinoma: epidemiology, risk factors and survival].

Authors:  M Pantel; O Guntinas-Lichius
Journal:  HNO       Date:  2012-01       Impact factor: 1.284

Review 4.  Treatment of early-stage glottic cancer: meta-analysis comparison of laser excision versus radiotherapy.

Authors:  Kevin M Higgins; Manish D Shah; Maurice J Ogaick; Danny Enepekides
Journal:  J Otolaryngol Head Neck Surg       Date:  2009-12

5.  Differences in the sex ratio of laryngeal cancer incidence rates by anatomic subsite.

Authors:  P C Yang; D B Thomas; J R Daling; S Davis
Journal:  J Clin Epidemiol       Date:  1989       Impact factor: 6.437

6.  Supraglottic and glottic carcinomas: epidemiologically distinct entities?

Authors:  Eduardo De Stefani; Paolo Boffetta; Hugo Deneo-Pellegrini; Paul Brennan; Pelayo Correa; Fernando Oreggia; Alvaro L Ronco; María Mendilaharsu
Journal:  Int J Cancer       Date:  2004-12-20       Impact factor: 7.396

7.  Voice outcome in T1a midcord glottic carcinoma: laser surgery vs radiotherapy.

Authors:  Elisabeth V Sjögren; Maya A van Rossum; Ton P M Langeveld; Marika S Voerman; Vivienne A H van de Kamp; Mark O W Friebel; Ron Wolterbeek; Robert J Baatenburg de Jong
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2008-09

8.  Radiotherapy or CO(2) laser surgery as treatment of T(1a) glottic carcinoma?

Authors:  Vera Mahler; Morten Boysen; Kjell Brøndbo
Journal:  Eur Arch Otorhinolaryngol       Date:  2009-11-08       Impact factor: 2.503

9.  Challenging a dogma--surgery yields superior long-term results for T1a squamous cell carcinoma of the glottic larynx compared to radiotherapy.

Authors:  D Thurnher; B M Erovic; F Frommlet; W Brannath; K Ehrenberger; B Jansen; E Selzer; M C Grasl
Journal:  Eur J Surg Oncol       Date:  2007-08-08       Impact factor: 4.424

10.  Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer.

Authors:  Arlene A Forastiere; Qiang Zhang; Randal S Weber; Moshe H Maor; Helmuth Goepfert; Thomas F Pajak; William Morrison; Bonnie Glisson; Andy Trotti; John A Ridge; Wade Thorstad; Henry Wagner; John F Ensley; Jay S Cooper
Journal:  J Clin Oncol       Date:  2012-11-26       Impact factor: 44.544

View more
  5 in total

1.  Epidemiology of laryngeal carcinoma in Germany, 1998-2011.

Authors:  Maximilian Peller; Alexander Katalinic; Barbara Wollenberg; Ingo U Teudt; Jens-E Meyer
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-02-15       Impact factor: 2.503

2.  Primary carcinoma of the larynx in females: A case series.

Authors:  Y Oukessou; A Chebaatha; O Berrada; R L Abada; S Rouadi; M Roubal; M Mahtar; M Regragui; M Karkouri
Journal:  Ann Med Surg (Lond)       Date:  2022-05-25

3.  Impact of stage, management and recurrence on survival rates in laryngeal cancer.

Authors:  Jesper Brandstorp-Boesen; Ragnhild Sørum Falk; Morten Boysen; Kjell Brøndbo
Journal:  PLoS One       Date:  2017-07-14       Impact factor: 3.240

4.  Role of T helper 17 cytokines in the tumour immune inflammation response of patients with laryngeal squamous cell carcinoma.

Authors:  Wei-Jing Tang; Lei Tao; Li-Ming Lu; Di Tang; Xiao-Lin Shi
Journal:  Oncol Lett       Date:  2017-05-25       Impact factor: 2.967

5.  Risk of Recurrence in Laryngeal Cancer.

Authors:  Jesper Brandstorp-Boesen; Ragnhild Sørum Falk; Jan Folkvard Evensen; Morten Boysen; Kjell Brøndbo
Journal:  PLoS One       Date:  2016-10-07       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.